What is Polypid Ltd.'s earnings per share (EPS)?

Polypid Ltd. (PYPD) reported diluted earnings per share of $2.09 for fiscal year 2025. This represents a -57.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Polypid Ltd. Financials

PYPD

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Polypid Ltd. (PYPD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Polypid Ltd. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.82x

For every $1 of reported earnings, Polypid Ltd. generates $0.82 in operating cash flow (-$27.9M OCF vs -$34.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-37.7x

Polypid Ltd. earns $-37.7 in operating income for every $1 of interest expense (-$33.0M vs $874K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$31.5M

YoY-19.3%

Polypid Ltd.'s EBITDA was -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 19.3% from the prior year.

Net Income

-$34.2M

YoY-17.7%

Polypid Ltd. reported -$34.2M in net income in fiscal year 2025. This represents a decrease of 17.7% from the prior year.

EPS (Diluted)

$2.09

YoY-57.4%

Polypid Ltd. earned $2.09 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 57.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$28.1M

YoY-27.5%

Polypid Ltd. generated -$28.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 27.5% from the prior year.

Cash & Debt

$6.4M

YoY-59.1%

5Y CAGR+8.2%

Polypid Ltd. held $6.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY+78.6%

Polypid Ltd. had 18M shares outstanding in fiscal year 2025. This represents an increase of 78.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-311.4%

YoY+66.3pp

5Y CAGR-260.7pp

Polypid Ltd.'s ROE was -311.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 66.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$23.8M

YoY+4.4%

5Y CAGR+7.0%

Polypid Ltd. invested $23.8M in research and development in fiscal year 2025. This represents an increase of 4.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$210K

YoY+176.3%

5Y CAGR-23.1%

Polypid Ltd. invested $210K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 176.3% from the prior year.

PYPD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$23.8M+4.4%	$22.8M+41.3%	$16.1M-42.3%	$28.0M-8.4%	$30.6M+80.2%	$17.0M
SG&A Expenses	$7.2M+68.1%	$4.3M-22.6%	$5.5M-31.0%	$8.0M-16.6%	$9.6M+24.7%	$7.7M
Operating Income	-$33.0M-17.6%	-$28.0M-22.6%	-$22.9M+41.2%	-$38.9M+9.9%	-$43.1M-64.2%	-$26.3M
Interest Expense	$874K-42.1%	$1.5M-6.7%	$1.6M+58.2%	$1.0M	N/A	N/A
Income Tax	$5K-88.1%	$42K-39.1%	$69K-46.5%	$129K	N/A	N/A
Net Income	-$34.2M-17.7%	-$29.0M-21.6%	-$23.9M+39.7%	-$39.6M+7.1%	-$42.6M-15.5%	-$36.9M
EPS (Diluted)	$2.09-57.4%	$4.91	$16.93	$61.09-10.5%	$68.27+1423.9%	$4.48

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$6.2M	N/A	$4.8M	N/A	$4.0M	N/A	$8.4M
SG&A Expenses	N/A	$2.5M	N/A	$1.1M	N/A	$1.5M	N/A	$2.2M
Operating Income	N/A	-$9.4M	N/A	-$6.1M	N/A	-$5.8M	N/A	-$11.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$53K	N/A	$2K	N/A	$10K	N/A	N/A
Net Income	N/A	-$10.0M	N/A	-$6.3M	N/A	-$5.8M	N/A	-$11.8M
EPS (Diluted)	N/A	$0.78	N/A	$1.25	N/A	$3.95	N/A	$0.61

PYPD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$22.3M-11.6%	$25.2M+64.1%	$15.4M-40.8%	$26.0M-41.3%	$44.2M-41.7%	$75.8M
Current Assets	$15.2M-8.1%	$16.6M+173.2%	$6.1M-57.3%	$14.2M-59.2%	$34.8M-26.2%	$47.2M
Cash & Equivalents	$6.4M-59.1%	$15.6M+194.6%	$5.3M-37.9%	$8.6M-12.9%	$9.8M+127.3%	$4.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.3M-35.4%	$17.5M+0.4%	$17.5M-13.3%	$20.1M+143.4%	$8.3M+169.5%	$3.1M
Current Liabilities	$7.7M-39.0%	$12.7M+74.0%	$7.3M-14.8%	$8.6M+5.9%	$8.1M+180.7%	$2.9M
Long-Term Debt	N/A	$634K-90.1%	$6.4M-15.8%	$7.6M	N/A	N/A
Total Equity	$11.0M+42.8%	$7.7M+466.6%	-$2.1M-136.0%	$5.8M-83.8%	$36.0M-50.6%	$72.8M
Retained Earnings	-$301.5M-12.8%	-$267.3M-12.2%	-$238.3M-11.1%	-$214.4M-22.6%	-$174.9M-32.2%	-$132.3M

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Total Assets	$22.3M-40.8%	$37.7M+49.4%	$25.2M+29.2%	$19.5M+27.0%	$15.4M-41.5%	$26.3M+1.1%	$26.0M-25.4%	$34.8M
Current Assets	$15.2M-49.2%	$30.0M+80.9%	$16.6M+69.5%	$9.8M+61.2%	$6.1M-61.5%	$15.8M+11.0%	$14.2M-43.3%	$25.0M
Cash & Equivalents	$6.4M-63.3%	$17.4M+11.6%	$15.6M+408.5%	$3.1M-42.1%	$5.3M+56.3%	$3.4M-60.3%	$8.6M-26.5%	$11.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.3M-34.1%	$17.2M-1.9%	$17.5M-2.2%	$17.9M+2.6%	$17.5M-2.5%	$17.9M-11.1%	$20.1M+28.2%	$15.7M
Current Liabilities	$7.7M-41.2%	$13.2M+3.7%	$12.7M+23.3%	$10.3M+41.2%	$7.3M+33.7%	$5.5M-36.3%	$8.6M-1.7%	$8.7M
Long-Term Debt	N/A	N/A	$634K-79.7%	$3.1M-51.0%	$6.4M-25.3%	$8.5M+12.7%	$7.6M	N/A
Total Equity	$11.0M-46.4%	$20.5M+166.5%	$7.7M+380.0%	$1.6M+176.4%	-$2.1M-125.1%	$8.3M+43.2%	$5.8M-69.5%	$19.1M
Retained Earnings	-$301.5M-5.6%	-$285.6M-6.8%	-$267.3M-6.5%	-$251.1M-5.3%	-$238.3M-5.3%	-$226.3M-5.6%	-$214.4M-8.0%	-$198.6M

PYPD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$27.9M-26.9%	-$22.0M-27.4%	-$17.2M+49.8%	-$34.3M-6.0%	-$32.4M-50.0%	-$21.6M
Capital Expenditures	$210K+176.3%	$76K-61.2%	$196K-88.9%	$1.8M-33.4%	$2.7M+239.7%	$781K
Free Cash Flow	-$28.1M-27.5%	-$22.0M-26.4%	-$17.4M+51.7%	-$36.1M-3.0%	-$35.0M-56.6%	-$22.4M
Investing Cash Flow	-$6.7M-1931.5%	-$330K-108.7%	$3.8M-77.0%	$16.6M-55.1%	$36.9M+190.5%	-$40.8M
Financing Cash Flow	$25.4M-21.7%	$32.4M+224.9%	$10.0M-39.3%	$16.4M+1488.8%	$1.0M-98.4%	$62.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PYPD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-311.4%+66.3pp	-377.7%	N/A	-678.6%-560.1pp	-118.5%-67.8pp	-50.7%
Return on Assets	-153.2%-38.1pp	-115.1%+40.2pp	-155.3%-2.9pp	-152.3%-56.0pp	-96.3%-47.7pp	-48.6%
Current Ratio	1.97+0.7	1.31+0.5	0.83-0.8	1.66-2.7	4.31-12.1	16.41
Debt-to-Equity	1.03+1.0	0.08+3.1	-3.04-4.3	1.30+1.1	0.23+0.2	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-48.7%	N/A	-393.1%	N/A	-69.9%	N/A	-62.0%
Return on Assets	N/A	-26.5%	N/A	-32.2%	N/A	-22.2%	N/A	-34.0%
Current Ratio	1.97-0.3	2.28+1.0	1.31+0.4	0.95+0.1	0.83-2.1	2.89+1.2	1.66-1.2	2.87
Debt-to-Equity	1.03+0.2	0.84+0.8	0.08-1.9	1.95+5.0	-3.04-4.1	1.02-0.3	1.30+0.5	0.82
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Cue Biopharma Inc CUE

$22.5M

Karyopharm Therapeutics Inc KPTI

$125.6M

Camp4 Therapeutics Corp. CAMP

$229.0M

Pds Biotechnology Corporation PDSB

$33.1M

Vtv Therapeutics VTVT

$156.2M

Frequently Asked Questions

Is Polypid Ltd. profitable?

No, Polypid Ltd. (PYPD) reported a net income of -$34.2M in fiscal year 2025.

What is Polypid Ltd.'s EBITDA?

Polypid Ltd. (PYPD) had EBITDA of -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Polypid Ltd.'s return on equity (ROE)?

Polypid Ltd. (PYPD) has a return on equity of -311.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Polypid Ltd.'s free cash flow?

Polypid Ltd. (PYPD) generated -$28.1M in free cash flow during fiscal year 2025. This represents a -27.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Polypid Ltd.'s operating cash flow?

Polypid Ltd. (PYPD) generated -$27.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Polypid Ltd.'s total assets?

Polypid Ltd. (PYPD) had $22.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Polypid Ltd.'s capital expenditures?

Polypid Ltd. (PYPD) invested $210K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Polypid Ltd. spend on research and development?

Polypid Ltd. (PYPD) invested $23.8M in research and development during fiscal year 2025.

How many shares does Polypid Ltd. have outstanding?

Polypid Ltd. (PYPD) had 18M shares outstanding as of fiscal year 2025.

What is Polypid Ltd.'s current ratio?

Polypid Ltd. (PYPD) had a current ratio of 1.97 as of fiscal year 2025, which is generally considered healthy.

What is Polypid Ltd.'s debt-to-equity ratio?

Polypid Ltd. (PYPD) had a debt-to-equity ratio of 1.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Polypid Ltd.'s return on assets (ROA)?

Polypid Ltd. (PYPD) had a return on assets of -153.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Polypid Ltd.'s cash runway?

Based on fiscal year 2025 data, Polypid Ltd. (PYPD) had $6.4M in cash against an annual operating cash burn of $27.9M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Polypid Ltd.'s Piotroski F-Score?

Polypid Ltd. (PYPD) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Polypid Ltd.'s earnings high quality?

Polypid Ltd. (PYPD) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Polypid Ltd. cover its interest payments?

Polypid Ltd. (PYPD) has an interest coverage ratio of -37.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.